Clinical Trials Sponsored by Vidac Pharma

Total 8277 results

LEO Pharma

Completed

A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) (LP0113-1123)

Skin and Connective Tissue Diseases

France
LEO Pharma

Completed

Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris

Acne Vulgaris

France
Vifor Pharma

Completed

Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

Atopic Dermatitis
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

Actinic Keratosis

Germany
UCB Pharma

Completed

UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)

Epilepsy | Pregnancy Complications | Seizures | Birth Defects

United States
LEO Pharma

Completed

A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris

Psoriasis Vulgaris

France
Cardeas Pharma

Completed

Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers

Healthy

United States
LEO Pharma

Completed

Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

Atopic Dermatitis

Germany
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

Actinic Keratosis

Germany
LEO Pharma

Completed

Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%

Actinic Keratosis

Australia, Germany
Innate Pharma

Completed

Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma (REMYKIR)

Multiple Myeloma

France
PLx Pharma

Completed

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

Diabetes Mellitus, Type 2

United States
LEO Pharma

Completed

LEO 29102 Single and Multiple Dose Study by Dermal Application

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects

Psoriasis Vulgaris

United Kingdom
Patara Pharma

Completed

Treatment of Refractory Chronic Cough With PA101

Refractory Chronic Cough

Netherlands, United Kingdom
Cardeas Pharma

Withdrawn

Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization

Pneumonia, Bacterial
Kiadis Pharma

Completed

Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States, Canada, Netherlands, Germany, Belgium, United Kingdom
AM-Pharma

Withdrawn

A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Proven Candidaemia (SLIC)

Candidaemia

Netherlands
UCB Pharma

Completed

Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).

Epilepsy

France, Poland, Belgium, Bulgaria, Switzerland, Finland
LEO Pharma

Completed

A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Terminated

Fucidin® Cream in the Treatment of Impetigo

Impetigo

Norway, Sweden
LEO Pharma

Completed

Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

An Irritation Study With New Calcipotriol Ointment Formulations in Healthy Subjects

Irritation

France
UCB Pharma

Completed

Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)

Crohn's Disease

Japan
UCB Pharma

Completed

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months (BALL)

Allergic Rhinitis | Chronic Urticaria

United States
Omega Pharma

Completed

Study on Hypertonic Saline Nasal Spray (PhytosunDecon)

Nasal Congestion

United Kingdom
Elro Pharma

Completed

Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors (IP N02)

All Solid Tumors

France, Belgium
Evgen Pharma

Completed

Sulforadex in Healthy Human Males MAD

Prostate Cancer

United Kingdom
UCB Pharma

Completed

Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body

Healthy Volunteers

Germany
UCB Pharma

Completed

Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.

Healthy

Germany
UCB Pharma

Completed

Named Patient Program With Rotigotine Transdermal System

Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine

United States
UCB Pharma

Completed

A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

Parkinson's Disease

United States
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease (SP715)

Parkinson's Disease

United States, Canada
UCB Pharma

Completed

Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)

Restless Legs Syndrome

Germany, Spain, Austria
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease. (SP512OL)

Early-Stage Parkinson's Disease

United States, Canada
UCB Pharma

Completed

Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa

Parkinson Disease, Idiopathic

Germany
UCB Pharma

Completed

Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB Pharma

Completed

A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

Parkinson's Disease

United States
UCB Pharma

Completed

Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome

Restless Legs Syndrome

Germany
UCB Pharma

Completed

A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

Restless Legs Syndrome

Germany
UCB Pharma

Completed

A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathy

United States
UCB Pharma

Completed

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Partial Seizures With or Without Secondary Generalization

Germany
UCB Pharma

Completed

SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Epilepsy
LEO Pharma

Completed

Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm

Actinic Keratosis

Australia
UCB Pharma

Completed

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) (RESTORE)

Restless Legs Syndrome

United States
UCB Pharma

Completed

Facial Thermography Study of Levocetirizine Versus Cetirizine

Anti-allergic Agents
LEO Pharma

Completed

Study on Thrombosis Therapy in German Cancer Patients

Cancer | Deep Vein Thrombosis | Pulmonary Embolism

Germany
LEO Pharma

Completed

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

Venous Thromboembolism

Canada
UCB Pharma

Withdrawn

Study of Epratuzumab in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, France, United Kingdom, Spain, Belgium, Netherlands, Canada, Brazil, Germany, Hungary, Czech Republic, Italy, Slovakia
UCB Pharma

Completed

Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms

Idiopathic Parkinson's Disease

Germany, Austria, Belgium, Bulgaria, Czech Republic, France, Hungary, Italy, Romania, Slovakia, Spain, Switzerland

3

Subscribe